Intuitive Surgical Forecasts $2.62B Q1 Revenue, EPS $2.11 Despite FDA Stapler Alert
Intuitive Surgical’s Q1 earnings forecast includes EPS of $2.11, up 17% year-over-year, and revenue of $2.62 billion, rising from $1.81 and $2.25 billion respectively. A recent FDA alert on high-risk stapling devices sent shares down 0.8%, while its P/E ratio stands at 57.8 with a debt-to-equity of just 0.017.
1. Earnings Projections
Analysts project Intuitive Surgical will report Q1 EPS of $2.11 versus $1.81 a year ago and revenue of $2.62 billion versus $2.25 billion, reflecting strong year-over-year growth ahead of the April 21 release. Top forecasters have raised estimates on both metrics following robust procedure volumes and order backlogs for da Vinci systems.
2. FDA Stapling Device Alert
The FDA issued an early alert regarding potential high-risk issues with Intuitive Surgical’s stapling devices, triggering a 0.8% stock decline and intensifying scrutiny over the safety of its robotic-assisted surgery components. This notice highlights regulatory risk as the company seeks broader stapler adoption in minimally invasive procedures.
3. Valuation and Financial Health
Intuitive Surgical trades at a P/E ratio of 57.8, signaling premium growth expectations, while maintaining a debt-to-equity ratio of 0.017, underscoring minimal leverage. These metrics reflect investor confidence in the company’s cash flow generation and financial stability amid the expanding surgical robotics market.